Efficacy and Field Safety of the Second-Generation, Highly Selective JAK1 Inhibitor Atinvicitinib for the Treatment of Canine Atopic Dermatitis A Multicentre, Blinded, Randomised, Placebo-Controlled Clinical Trial in Client-Owned Dogs.

Clinical Context

Peer-reviewed veterinary literature continues to shape everyday decision-making for canine patients, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.

What the Study Evaluated

A study published in Veterinary dermatology in 2026 evaluated efficacy and Field Safety of the Second-Generation, Highly Selective JAK1 Inhibitor Atinvicitinib for the Treatment of Canine Atopic Dermatitis: A Multicentre, Blinded, Randomised, Placebo-Controlled Clinical Trial in Client-Owned Dogs..

Key Findings

Janus kinase (JAK) inhibitors alleviate pruritus and clinical signs of canine atopic dermatitis (cAD). To confirm the optimal dosing regimen of atinvicitinib, a second-generation highly selective inhibitor of JAK1 in dogs. Sixty-one client-owned dogs, ≥ 12 months and ≥ 2 kg, with cAD. In a randomised, masked, placebo-controlled clinical trial, dogs received atinvicitinib, with food, at 0.8-1.2 mg/kg, once daily for 28 days (q.d. group, n = 21) or 0.4-0.6 mg/kg twice daily for 14 days followed by once daily dosing for 14 days (b.i.d.-q.d. group, n = 21); or placebo b.i.d.-q.d. (control group, n = 19). Owners assessed pruritus (Day [D]0-7,...

Why It Matters for Veterinary Professionals

For veterinary professionals, the practical value of this work lies in how the findings may support more structured clinical assessment, clearer monitoring, and more informed decisions for canine patients.

Practical Interpretation

The results should be interpreted in the context of the study design, population, inclusion criteria, and clinical setting. Application in practice should consider patient-specific risk factors, available diagnostics, local standards of care, and clinician judgment.

Clinical Takeaway

Overall, the study adds useful evidence for clinicians seeking to align daily practice with current veterinary research while maintaining a balanced, case-by-case approach.

• Read the full article here: https://pubmed.ncbi.nlm.nih.gov/42754303/